A new treatment option for managing refractory blood cancer, specifically Diffuse Large B-Cell Lymphoma (DLBCL), has completed its approval process in Korea. This approval primarily…

The management dispute within Hanmi Pharmaceutical Group that has heated up the pharmaceutical and biotech industry for over 6months this year has come to an end. On the 10th, Lim Jong-yoon, an…

HK Inno.N Corporation is emerging as a company to watch in the second half of the year, following strong performance and promising U.S. clinical trial results. On the 9th, the securities industry…

Celltrion has announced that their biosimilar Omvoh (CT-P39), a treatment for allergic asthma and chronic idiopathic urticaria, has been approved by the UK's Medicines and Healthcare products…

Song Young-sook, chairwoman of Hanmi Pharm. Co., Ltd. has stepped down from the management of the company and said he will support a professional management system centred on Hanyang Precision…

The FDA approval of Eli Lilly's 'Donanemab' (marketed as Kisunla), the third Alzheimer's treatment globally, is anticipated to create a positive ripple effect for radiopharmaceutical companies…

ABL Bio has announced its ambition to become a global leader in the targeted cancer therapy market through the development of antibody-drug conjugates (ADCs) utilizing bispecific antibodies. On the…

GC Biopharma announced on the 2nd that it has signed a contract with a major Pharmacy Benefit Manager (PBM) in the United States to list ‘Alyglo’ in their formulary. Alyglo is an immune…

Samsung Bioepis has announced that its biosimilar to Stelara, named ‘Pyzchiva’ (project name SB17, active ingredient ustekinumab), has received approval from the U.S. Food and Drug Administration…

Yuhan Corporation Receives Approval for Phase 1 Clinical Trial of Gaucher Disease Treatment Yuhan Corporation has taken its first step towards developing a treatment for a rare disease. The company…